secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009141
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q1 net loss $23.9M; IND for MRT-2359 expected mid-2022
-----------------------------------------------------------------

- Net loss $23.9M for Q1 2022 vs $12.3M in Q1 2021; R&D spend $17.9M.
- Cash position $322.5M as of March 31, 2022; runway into late 2024.
- IND submission for GSPT1 degrader MRT-2359 on track for mid-2022; initial focus on NSCLC and SCLC.
- Preclinical data at AACR 2022 support MRT-2359 in Myc-driven solid tumors.
- New collaboration with EPFL to integrate AI engine with MaSIF technology for novel degrader discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017022009141/0000950170-22-009141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017022009141/glue-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer